Related Experiment Videos
Interferon-beta induction through toll-like receptor 3 depends on double-stranded RNA structure
Satoyo Okahira1, Fumiko Nishikawa, Satoshi Nishikawa
1Department of Immunology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Higashinari-ku, Osaka, Japan.
DNA and Cell Biology
|October 18, 2005
Summary
Toll-like receptor 3 (TLR3) recognizes specific double-stranded RNA (dsRNA) structures, distinct from those targeted by intracellular proteins. Modified dsRNAs can block TLR3-mediated interferon-beta production, impacting antiviral immunity.
Area of Science:
- Immunology
- Virology
- Molecular Biology
Background:
- Type I interferons (IFN-alpha/beta) are crucial for antiviral immunity.
- Interferon-beta (IFN-beta) production is induced by viral infection or double-stranded RNA (dsRNA).
- Toll-like receptor 3 (TLR3) recognizes extracellular dsRNA, activating IFN-beta production.
Purpose of the Study:
- To analyze the specific dsRNA structures that induce TLR3-mediated IFN-beta production.
- To compare dsRNA recognition by TLR3 with intracellular dsRNA-binding proteins.
- To investigate the mechanism of dsRNA recognition by TLR3.
Main Methods:
- Utilized various synthetic RNA duplexes to study dsRNA structure-activity relationships.
- Assessed IFN-beta production in fibroblasts and dendritic cells (DCs) upon stimulation with different dsRNAs.
- Investigated the inhibitory effects of modified dsRNAs and poly(dI:dC) on TLR3 signaling.
Main Results:
- TLR3 preferentially recognizes polyriboinocinic:polyribocytidylic acid (poly(I:C)) over synthetic virus-derived dsRNAs.
- Modifications to cytidylic acid in dsRNA abolished IFN-beta induction and inhibited poly(I:C)-induced responses.
- Poly(dI:dC) also inhibited poly(I:C)-induced IFN-beta production, suggesting competition for receptor binding.
Conclusions:
- TLR3 recognizes a unique dsRNA structure distinct from intracellular dsRNA-binding proteins.
- Modified dsRNAs can act as antagonists of TLR3 signaling.
- Understanding TLR3's dsRNA recognition mechanism is key for developing antiviral therapies.